Soleno Therapeutics DCCR Securities Lawsuits
Analysis based on 83 articles · First reported Apr 01, 2026 · Last updated May 05, 2026
The multiple class action lawsuits against MiNK Therapeutics, alleging securities fraud and misleading statements regarding its drug DCCR's safety and commercial viability, have led to significant investor losses and a sharp decline in MiNK Therapeutics' stock price. This event highlights the increased scrutiny on biotechnology companies' clinical trial disclosures and the potential for legal and reputational fallout from adverse drug safety reports.
Multiple investor-rights law firms, including The Schall Law Firm, Faruqi & Faruqi, Bronstein, Gewirtz & Grossman, LLC, The Law Offices of Frank R. Cruz, Rosen Law Firm, and Pomerantz LLP, have filed class action lawsuits against MiNK Therapeutics. These lawsuits allege that MiNK Therapeutics made false and misleading statements to investors between March 26, 2025, and November 4, 2025, regarding its drug candidate, diazoxide choline extended-release tablets (DCCR), for treating hyperphagia in individuals with Prader-Willi syndrome (PWS). The complaints claim that MiNK Therapeutics systematically downplayed or concealed significant safety concerns, including excess fluid retention and a patient death, and misrepresented DCCR's commercial viability. A critical report by Scorpion Capital on August 15, 2025, a subsequent disclosure of a patient death on September 10, 2025, and MiNK Therapeutics' Q3 2025 financial results on November 4, 2025, which revealed disruptions to DCCR's launch and increased discontinuations, all contributed to substantial declines in MiNK Therapeutics' stock price. Investors are encouraged to join the class actions before the May 5, 2026, lead plaintiff deadline.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard